Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Merck Completes Acquisition of Themis
Details : An initial focus of this agreement is acceleration of the development of a measles vector-based SARS-CoV-2 vaccine candidate. This candidate is currently in pre-clinical development, and clinical studies are planned to start later in 2020.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 19, 2020
Lead Product(s) : SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The planned acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform, and is expected to accelerate the development of Themis’ COVID-19 vaccine candidate.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
May 26, 2020
Lead Product(s) : SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
